cagrisema phase 3 results 2025 semaglutide cagrilintide obesity Novo Nordisk shares plunge after drug trial disappoints Novo Nordisk's CagriSema outperforms Ozempic – Cagrilintide–Semaglutide in Adults with Overweight

But that's not the only thing the medication had changed

Continuous glucose monitoring systems: a review

Hypoglycaemia (low blood glucose) is uncommon when Ozempic is used as monotherapy, as its glucose-lowering effect is glucose-dependent

Stopping is reasonable only if you've achieved your weight goal, sustained behavioral changes for months, and have a clear plan to prevent regain through diet and exercise

If you feel more nauseated when increasing doses, go for a slow titration and schedule small, bland protein snacks instead of skipping doses

doi: 10.5935/1518-0557.20130052 52 BuhlingKSchumacherAEulenburgCZLaakmannE